Novo Nordisk A/S

Eli Lilly and Company

Danish pharmaceutical giant Novo Nordisk said its obesity drug Wegovy reduces cardiovascular risks more effectively than its main competitors. The company's shares jumped 3% as a result.

Best-selling Novo reduces heart risks more effectively than competitor, trial shows

The negative outlook for the company has already come true, an HSBC analyst thought

Wall Street's only bearish on Eli Lilly stock has changed its mind

NVIDIA Corporation

EchoStar Corporation

Okta, Inc.

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: Nvidia's quarterly report in focus

By contrast, the shares of Eli Lilly's competitor, Ozempic manufacturer Novo Nordisk, fell 4%

Eli Lilly's weight loss pill has passed one of the key phases of testing. Shares rose

Viking Therapeutics, Inc.

Side effects of Viking's obesity pill upset investors

Viking shares fall 45% due to drug tests. Have the risks for Novo and Eli been reduced?

Wegovy is first-in-class approved for the treatment of liver disease, but its exclusivity is threatened by US-based Eli Lilly

Novo Nordisk shares rise after approval of Wegovy to treat liver disease

Cisco Systems, Inc.

Equinox Gold Corp.

Walmart Inc.

Morning in New York: quotes are driven by cautious optimism

Block, Inc.

Rocket Lab Corporation

Tesla, Inc.

Morning in New York: investors need a breather


In contrast, the securities of Eli Lilly's main competitor, Danish Novo Nordisk, rose in price by almost 7%


Eli Lilly has disappointed with the outcome of a weight loss pill trial. Shares are down 15%


Over the past year - from July 2024 to August 2025 - Novo Nordisk's stock, <a href="https://oninvest.com/issuers/novo-b-co">has lost</a> nearly 70% in value. That's a fantastic collapse for a company that makes sought-after diabetes and weight-loss drugs&nbsp; and is showing good revenue and profit growth. What happened to Novo Nordisk and how much of this investor reaction is justified?

The Novo Nordisk case: how the creator of Ozempic lost leadership in the market it created

Apple Inc.

DoorDash, Inc.

Morning in New York: foreign trade agenda remains in focus

After two worsening of the annual forecast and the change of the head of the company, the market is cautious
